Polypill protects MAFLD patients from cardiovascular events and mortality : a prospective trial
© 2023. Asian Pacific Association for the Study of the Liver..
BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel term that distinguishes patients at risk of adverse clinical outcomes with higher accuracy than those with non-alcoholic fatty liver disease (NAFLD). Cardiovascular mortality is the leading cause of death in MAFLD. The current literature lacks large-scale prospective studies that address preventive approaches for cardiovascular health in MAFLD. We investigated whether MAFLD patients benefit from a fixed-dose combination therapy (Aspirin, hydrochlorothiazide, atorvastatin, valsartan), known as a Polypill.
METHODS: Analysis was performed (stratified based on MAFLD status) of a clinical trial that included 1596 individuals randomly allocated to an intervention (polypill) or a control (usual care) group. Patients were followed up for five years for any adverse drug reaction, major cardiovascular events, and mortality. Univariable and multivariable survival analyses were performed, and the interaction level was assessed by R programming.
RESULTS: Patients who consumed the polypill had significantly lower hazard ratios of major cardiovascular events incidence (HR 0.56, 95% CI 0.41-0.78) and cardiovascular mortality (HR 0.41, 95% CI 0.2-0.86) compared to the control group. Polypill showed significantly better results in lowering cardiovascular events in MAFLD patients than in the general population. (p-value for interaction: 0.028). Moreover, comparing those patients who had high adherence to the Polypill, with the control group, further enhanced the results.
CONCLUSIONS: Major cardiovascular events are prevented in MAFLD patients who consume the Polypill. MAFLD patients benefit from the Polypill more than the general population.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:17 |
|---|---|
| Enthalten in: |
Hepatology international - 17(2023), 4 vom: 25. Aug., Seite 882-888 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramandi, Alireza [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.07.2023 Date Revised 28.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12072-023-10542-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357299256 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357299256 | ||
| 003 | DE-627 | ||
| 005 | 20231226072300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12072-023-10542-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357299256 | ||
| 035 | |a (NLM)37227560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramandi, Alireza |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Polypill protects MAFLD patients from cardiovascular events and mortality |b a prospective trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.07.2023 | ||
| 500 | |a Date Revised 28.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Asian Pacific Association for the Study of the Liver. | ||
| 520 | |a BACKGROUND: Metabolic dysfunction-associated fatty liver disease (MAFLD) is a novel term that distinguishes patients at risk of adverse clinical outcomes with higher accuracy than those with non-alcoholic fatty liver disease (NAFLD). Cardiovascular mortality is the leading cause of death in MAFLD. The current literature lacks large-scale prospective studies that address preventive approaches for cardiovascular health in MAFLD. We investigated whether MAFLD patients benefit from a fixed-dose combination therapy (Aspirin, hydrochlorothiazide, atorvastatin, valsartan), known as a Polypill | ||
| 520 | |a METHODS: Analysis was performed (stratified based on MAFLD status) of a clinical trial that included 1596 individuals randomly allocated to an intervention (polypill) or a control (usual care) group. Patients were followed up for five years for any adverse drug reaction, major cardiovascular events, and mortality. Univariable and multivariable survival analyses were performed, and the interaction level was assessed by R programming | ||
| 520 | |a RESULTS: Patients who consumed the polypill had significantly lower hazard ratios of major cardiovascular events incidence (HR 0.56, 95% CI 0.41-0.78) and cardiovascular mortality (HR 0.41, 95% CI 0.2-0.86) compared to the control group. Polypill showed significantly better results in lowering cardiovascular events in MAFLD patients than in the general population. (p-value for interaction: 0.028). Moreover, comparing those patients who had high adherence to the Polypill, with the control group, further enhanced the results | ||
| 520 | |a CONCLUSIONS: Major cardiovascular events are prevented in MAFLD patients who consume the Polypill. MAFLD patients benefit from the Polypill more than the general population | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Major cardiovascular events | |
| 650 | 4 | |a Metabolic dysfunction-associated fatty liver disease (MAFLD) | |
| 650 | 4 | |a Prevention | |
| 650 | 4 | |a Randomized open-labeled trial | |
| 650 | 7 | |a Aspirin |2 NLM | |
| 650 | 7 | |a R16CO5Y76E |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a George, Jacob |e verfasserin |4 aut | |
| 700 | 1 | |a Merat, Shahin |e verfasserin |4 aut | |
| 700 | 1 | |a Jafari, Elham |e verfasserin |4 aut | |
| 700 | 1 | |a Sharafkhah, Maryam |e verfasserin |4 aut | |
| 700 | 1 | |a Radmard, Amir Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Nateghi Baygi, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Delavari, Alireza |e verfasserin |4 aut | |
| 700 | 1 | |a Mohammadi, Zahra |e verfasserin |4 aut | |
| 700 | 1 | |a Poustchi, Hossein |e verfasserin |4 aut | |
| 700 | 1 | |a Malekzadeh, Reza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology international |d 2007 |g 17(2023), 4 vom: 25. Aug., Seite 882-888 |w (DE-627)NLM190585528 |x 1936-0541 |7 nnns |
| 773 | 1 | 8 | |g volume:17 |g year:2023 |g number:4 |g day:25 |g month:08 |g pages:882-888 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12072-023-10542-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 17 |j 2023 |e 4 |b 25 |c 08 |h 882-888 | ||